Syncromune®

Join us today at #ECIO2026 in Auditorium 3 @ 8:30am for Dr. Kee's presentation "Abscopal effects of an image-guided percutaneous combination device/drug immunotherapy approach to metastatic prostate cancer" during the SP 413 – Y90 and novel therapies session! #ECIO2026 #Syncromune #CancerImmunotherapy #ProstateCancer #Intratumoral #SYNCT

Check out our presentation at the European Conference on Interventional Oncology 2026! Syncromune is pleased to announce that Stephen Kee, MD, will deliver an oral presentation on the potential of SYNC-T Therapy SV-102 for the treatment of metastatic prostate cancer at ECIO 2026 in Basel. Our combination drug/device immunotherapy uses an image-guided percutaneous approach to place a cryo needle/infusion sheath system into a target tumor, utilizing the same device to perform both cryolysis and infusion of a multi-target drug directly into the lysed zone. The therapy aims to elicit a systemic anti-tumor response, empowering the immune system to recognize and attack both primary and metastatic lesions. We look forward to engaging with the interventional oncology community and sharing the future vision of our SYNC-T locoregional immunotherapeutic platform that is designed to tackle the toughest challenges in treating metastatic solid tumors. #ECIO2026 #InterventionalOncology #Immunotherapy #Oncology #SYNCT #Syncromune #ProstateCancer #Intratumoral

Syncromune is excited to be attending the #IPCS26 this year to connect with leading prostate cancer experts and share the latest on our novel SYNC-T in situ immunotherapy for metastatic solid tumors! We are currently enrolling our Phase 2 LEGION-100 trial for our lead candidate SV-102 in mCRPC. Learn more about referring a patient or becoming a trial site: legion100trial.com #ProstateCancer #CancerImmunotherapy #Syncromune #SYNCT

Ready to ‘Sync Up’ in San Diego? Meet Dr. Charles Link, Executive Chairman and co-founder of Syncromune, today (April 20) at the ongoing American Association for Cancer Research Annual Meeting 2026, Booth #3752. This is your opportunity to engage with a true pioneer in medical oncology and get a firsthand look at SYNC-T™, our intratumoral combination drug/device immunotherapy platform designed to drive a smarter, systemic immune response against cancer. We’re actively enrolling patients and expanding trial sites for LEGION-100, our Phase 2 study in men with metastatic castration-resistant prostate cancer (mCRPC). Interested in becoming a site or referring patients? Let’s talk! Stop by Booth #3752 today. You won’t want to miss the opportunity to ‘sync up’ with Chuck! Explore more: Legion100Trial.com #AACR26 #ProstateCancer #mCRPC #Oncology #CancerResearch #SYNCT

Visit us at the 2026 AACR Annual Meeting in San Diego to learn about SYNC-T™, our combination intratumoral drug/device immunotherapy platform. We are now enrolling and recruiting trial sites for our Phase 2 LEGION-100 trial in men with metastatic castration-resistant prostate cancer (mCRPC). Stop by Booth #3752. Learn more: Legion100Trial.com #AACR26 #ProstateCancer #mCRPC #Oncology #CancerResearch #SYNCT

We're heading to #AACR26! Syncromune will be at this year's American Association for Cancer Research Annual Meeting taking place April 17–22, 2026 in San Diego, and we'd love to ‘sync up.’ Stop by our Booth #3752 to learn more about SYNC-T™, our in situ combination drug/device immunotherapy platform designed to synchronize the immune system to recognize and destroy cancer throughout the body. LEGION-100, our ongoing Phase 2 clinical trial evaluating SYNC-T Therapy SV-102 in men with metastatic castration-resistant prostate cancer (mCRPC), is actively enrolling patients and recruiting clinical trial sites. Please connect with us if you are interested in becoming a clinical trial site or want to learn more about how you can refer your mCRPC patients. Whether you're a clinician, researcher, or simply passionate about advancing cancer care, we’d love the opportunity to discuss our novel treatment approach for metastatic solid tumors! Find us at AACR: Booth #3752 Learn more: Legion100Trial.com #AACR26 #Oncology #ProstateCancer #mCRPC #CancerImmunotherapy #ClinicalTrials #LEGION100 #SYNCT #Biotech

Thank you @GRUrology and #IPCU36 attendees for a great meeting! Syncromune's abstract "Effective Resolution of Bone Metastases in Subjects with Metastatic Prostate Cancer Using SYNC-T Therapy SV-102" was presented by Gerald Andriole, M.D. @uropro, Syncromune's Chief Medical Officer, Urology, and can be read here: lnkd.in/gaq8dqXf Syncromune is expanding on these data in the LEGION-100 Phase 2 trial for mCRPC, which is currently enrolling and recruiting trial sites. Visit legion100trial.com to learn more. #ProstateCancer #Syncromune #Immunotherapy #Urology #LEGION100

Thank you #SUO25. We were proud to share Phase 1 SYNC-T data showing 54% of metastatic prostate cancer patients had complete resolution of bone metastases and favorable tolerability. SYNC-T is now being studied for mCRPC in the Phase 2 LEGION-100 trial. Details: bit.ly/48jYaU5

Today, Syncromune will present new Phase 1 data at #SUO25 highlighting resolution of bone metastases in men with advanced prostate cancer treated with SYNC-T Therapy SV-102. Don’t miss our poster #175 from 4:30-5:30pm MST! bit.ly/48jYaU5

Thanks to everyone who connected with us at #SITC2025! We’re expanding the LEGION-100 trial and welcome new investigator sites interested in advancing in situ combination immunotherapy for prostate cancer. Learn more at legion100trial.com or reach out at info@legion100trial.com #ClinicalResearch #Syncromune

Join Syncromune tomorrow at #SITC2025 to learn how SYNC-T® could redefine the treatment of mCRPC and how your site can be part of the LEGION-100 trial. Learn more about the event and register here: exploresync-t.com #ClinicalTrials #CancerResearch

Heading to #SITC2025? Join us to learn more about the LEGION-100 trial for patients with advanced prostate cancer and how your clinical site could be involved. Learn more at exploresync-t.com

Honored to Attend the 32nd Annual @PCFnews Scientific Retreat! This past weekend, Syncromune had the privilege of attending the 32nd Annual #PCFRetreat25, where some of the brightest minds in prostate cancer research and clinical innovation gathered to share groundbreaking discoveries. We were proud to present Phase 1 data in metastatic prostate cancer, highlighting encouraging results from our combination immunotherapy, SYNC-T Therapy SV-102. We are grateful to be part of such a dedicated community working to accelerate progress for men living with prostate cancer. #ProstateCancer #CancerResearch #Immunotherapy #PCFRetreat2025

Prostate Cancer Awareness Month may be ending, but our commitment to patients and families goes on. 💙 Syncromune is dedicated to advancing new therapies for advanced #ProstateCancer through innovation in immunotherapy. #ProstateCancerAwareness #mCRPC #SYNC_T

We are committed to advancing treatment options for men with mCRPC. Our legion-100 trial is now enrolling. Learn if you or a loved one may qualify: legion100trial.com #ProstateCancerAwareness #mCRPC #ClinicalResearch

1 in 8 men will face prostate cancer in their lifetime. We’re working to bring hope with new immunotherapies for advanced disease. #ProstateCancer #mCRPC #clinicalresearch

Syncromune CEO Eamonn Hobbs joined The BioHub Podcast at #BIO2025 to discuss: ✅ 87% ORR & 53% CR in mCRPC in Phase 1 ✅ Phase 2 LEGION-100 trial ✅ $100M Series A Tune in to hear how we’re innovating immunotherapy for solid tumors: youtube.com/playlist?list=… #ASCO25 #ProstateCancer #Immunotherapy

@Urotoday discussed our recent #ASCO25 data! Our in situ immunotherapy, SYNC-T, demonstrated an 87% ORR and 53% CR in patients with #mCRPC, one of the hardest-to-treat cancers. Read more here: bit.ly/44c7s2p #ProstateCancer #Immunotherapy #mCRPC #ASCO25